Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 …

Jan 5, 2025 · NASDAQ IOVA opened at $7.65 on Thursday. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -5.13 and a beta of 0.57. The company has a 50-day simple …

$23.00
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 …

2 weeks from now

Jan 5, 2025 · NASDAQ IOVA opened at $7.65 on Thursday. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -5.13 and a beta of 0.57. The company has a 50-day simple …

etfdailynews.com

$23.00
OFF

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

2 weeks from now

5 days ago · Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 Average Target Price from Brokerages. January 5, 2025 | americanbankingnews.com ... Iovance …

marketbeat.com

$23.00
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 …

2 weeks from now

Jan 5, 2025 · Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently …

americanbankingnews.com

63%
OFF

IOVA.OQ - | Stock Price & Latest News | Reuters

2 weeks from now

Dec 13, 2024 · Iovance Biotherapeutics Inc IOVA.OQ. Official Data Partner. Latest Trade. trading lower 7.83 USD. Change-0.13 % Change-1.63% Negative As of Dec 14, 2024. Values delayed …

reuters.com

$5.91
OFF

Oversold Conditions For Iovance Biotherapeutics (IOVA)

2 weeks from now

1 day ago · In trading on Monday, shares of Iovance Biotherapeutics Inc (Symbol: IOVA) entered into oversold territory, hitting an RSI reading of 26.3, after changing hands as low as $5.91 per …

nasdaq.com

$58
OFF

Iovance Biotherapeutics Reports Financial Results And Corporate …

2 weeks from now

Nov 7, 2024 · Iovance Biotherapeutics reported strong Q3 2024 results with $58.6M in total product revenue, including $42.1M from Amtagvi and $16.5M from Proleukin sales.The …

stocktitan.net

11%
OFF

Iovance Biotherapeutics (IOVA) Market Capitalization Overview

2 weeks from now

2 days ago · As of Jan 13, 2025, Iovance Biotherapeutics (IOVA) has a market capitalization of $1.77B.Over the past 30 days, its market cap has decreased by -14.11%, while in the last 12 …

public.com

8%
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares ... - MarketBeat

2 weeks from now

Dec 21, 2024 · Barclays PLC increased its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 118.8% in the third quarter, according to its most recent 13F filing with the …

marketbeat.com

2%
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought By …

2 weeks from now

Dec 18, 2024 · Fmr LLC lifted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 79.2% in the third quarter, according to its most recent Form 13F filing with the …

defenseworld.net

56%
OFF

A Peek At Iovance Biotherapeutics's Future Earnings

2 weeks from now

Nov 6, 2024 · Stock Performance Shares of Iovance Biotherapeutics were trading at $11.66 as of November 05. Over the last 52-week period, shares are up 204.56%.

nasdaq.com

25%
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too …

2 weeks from now

4 days ago · To the annoyance of some shareholders, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are down a considerable 25% in the last month, which continues a …

simplywall.st

$7.22
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired By ...

2 weeks from now

Dec 20, 2024 · Iovance Biotherapeutics Trading Down 0.6 %. Shares of Iovance Biotherapeutics stock opened at $7.22 on Friday. Iovance Biotherapeutics, Inc. has a 52 week low of $6.70 …

etfdailynews.com

FAQs about Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 … Coupon?

Should you buy iovance Biotherapeutics (Iova) stock?

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. ...

How much did iovance Biotherapeutics earn in a quarter?

Iovance Biotherapeutics last announced its earnings data on May 9th, 2024. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.03. The business earned $0.72 million during the quarter, compared to the consensus estimate of $1.99 million. ...

How do I receive news & ratings for iovance Biotherapeutics?

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...

Who is iovance Biotherapeutics?

(Get Free Report Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. ...

When is iovance Biotherapeutics' next earnings release date?

Iovance Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on IOVA's earnings history. Did Iovance Biotherapeutics beat their earnings estimates last quarter? ...

What is iovance Biotherapeutics' Digital Dollar?

This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar. Iovance Biotherapeutics last announced its earnings data on May 9th, 2024. ...